Addressing Excipient Variability in Formulation Design and Drug Development

Variability of excipient attributes has often been characterized into source-to-source variability or lot-to-lot variability from the same source or vendor, also termed intersource variability or interlot variability, respectively. The former is controlled much readily by establishing and controlling the source of raw materials. The latter is often difficult to identify, understand, and control. This chapter primarily focuses on the interlot variability of excipients from the same grade and source or supplier and provides a comprehensive framework of approaches that can be proactively adopted to understand and investigate lot-to-lot variability encountered in excipients, with an intent to building a robust drug product with a sound control strategy around critical material attributes.

[1]  L. Augsburger,et al.  The Influence of Product Brand-to-Brand Variability on Superdisintegrant Performance A Case Study with Croscarmellose Sodium , 2006, Pharmaceutical development and technology.

[2]  Divyakant Desai,et al.  Impact of Excipient Interactions on Solid Dosage Form Stability , 2012, Pharmaceutical Research.

[3]  J. L. Gómez-Amoza,et al.  Intersupplier and interlot variability in hydroxypropyl celluloses: implications for theophylline release from matrix tablets , 1998 .

[4]  P. York,et al.  Characterisation of the surface properties of α-lactose monohydrate with inverse gas chromatography, used to detect batch variation , 1996 .

[5]  E. Doelker,et al.  Comparative Tableting Properties of Sixteen Microcrystalline Celluloses , 1987 .

[6]  A. Narang,et al.  Chapter 6 – Excipient Compatibility , 2009 .

[7]  J. Kushner,et al.  A quality-by-design study for an immediate-release tablet platform: examining the relative impact of active pharmaceutical ingredient properties, processing methods, and excipient variability on drug product quality attributes. , 2014, Journal of pharmaceutical sciences.

[8]  J. Sjögren,et al.  Evaluation of some lubricants by the comparison of friction coefficients and tablet properties. , 1981, Acta pharmaceutica Suecica.

[9]  P. York,et al.  Particle size effects on the dehydration of dicalcium phosphate dihydrate powders , 1994 .

[10]  J. Kushner,et al.  Examining the impact of excipient material property variation on drug product quality attributes: a quality-by-design study for a roller compacted, immediate release tablet. , 2011, Journal of pharmaceutical sciences.

[11]  A. Narang,et al.  Impact of Excipient Interactions on Drug Bioavailability from Solid Dosage Forms , 2012, Pharmaceutical Research.

[12]  Joseph Kushner Utilizing quantitative certificate of analysis data to assess the amount of excipient lot-to-lot variability sampled during drug product development , 2013, Pharmaceutical development and technology.

[13]  M. Manning,et al.  Effects of Tween 20 and Tween 80 on the stability of Albutropin during agitation. , 2005, Journal of pharmaceutical sciences.

[14]  R. Johnson,et al.  Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine. , 1998, Journal of pharmaceutical sciences.

[15]  Jérôme Barra,et al.  Influence of the Physicochemical Variability of Magnesium Stearate on Its Lubricant Properties: Possible Solutions , 1996 .

[16]  J. L. Gómez-Amoza,et al.  The effect of country of origin on the properties of dicalcium phosphate dihydrate powder , 1994 .

[17]  Lawrence X. Yu Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control , 2008, Pharmaceutical Research.

[18]  Robert A Reed,et al.  The role of excipients and package components in the photostability of liquid formulations. , 2003, PDA journal of pharmaceutical science and technology.

[19]  S. Alsaidan,et al.  Improved dissolution rate of indomethacin by adsorbents. , 1998, Drug development and industrial pharmacy.

[20]  R. Williams,et al.  Compaction properties of microcrystalline cellulose using tableting indices , 1997 .

[21]  Compendial standards and excipient performance in the QbD era: USP excipient performance chapter 〈1059〉 , 2011 .

[22]  D. Bindra,et al.  Reversible and pH‐dependent weak drug‐excipient binding does not affect oral bioavailability of high dose drugs , 2012, The Journal of pharmacy and pharmacology.

[23]  S. Moghimi,et al.  Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. , 2004, Biochimica et biophysica acta.

[24]  S. Varia,et al.  Effects of variations in physicochemical properties of glyceryl monostearate on the stability of an oil-in- , 1989 .

[25]  J. L. Gómez-Amoza,et al.  Interlot variability of carbomer 934 , 1993 .

[26]  Vivek S. Dave,et al.  Excipient variability and its impact on dosage form functionality. , 2015, Journal of pharmaceutical sciences.

[27]  Torbjörn Lundstedt,et al.  Robustness Testing of a Tablet Formulation Using Multivariate Design , 2006, Drug development and industrial pharmacy.

[28]  Ganeshkumar A. Subramanian,et al.  Mechanistic basis for the effects of process parameters on quality attributes in high shear wet granulation. , 2012, International journal of pharmaceutics.

[29]  R. Pinal,et al.  Elucidating Raw Material Variability—Importance of Surface Properties and Functionality in Pharmaceutical Powders , 2009, AAPS PharmSciTech.

[30]  L. Augsburger,et al.  Increasing the Dissolution Rate of a Low-Solubility Drug Through a Crystalline-Amorphous Transition: A Case Study with Indomethicin , 2008, Drug development and industrial pharmacy.

[31]  Physicochemical Interactions in Solid Dosage Forms , 2012, Pharmaceutical Research.

[32]  A. Narang,et al.  Effect of antioxidants and silicates on peroxides in povidone. , 2012, Journal of pharmaceutical sciences.

[33]  C. Rhodes,et al.  Effect of molecular structure variation on the disintegrant action of sodium starch glycolate. , 1985, Journal of pharmaceutical sciences.

[34]  Ajit S. Narang,et al.  Reactive Impurities in Excipients: Profiling, Identification and Mitigation of Drug–Excipient Incompatibility , 2011, AAPS PharmSciTech.

[35]  A. Narang,et al.  Formation of reactive impurities in aqueous and neat polyethylene glycol 400 and effects of antioxidants and oxidation inducers. , 2012, Journal of pharmaceutical sciences.

[36]  Huiquan Wu,et al.  Quality-by-design (QbD): an integrated multivariate approach for the component quantification in powder blends. , 2009, International journal of pharmaceutics.

[37]  Hui Xu,et al.  Evaluation of hydroperoxides in common pharmaceutical excipients. , 2007, Journal of pharmaceutical sciences.